Paul K. Drain

ORCID: 0000-0002-9569-4097
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • HIV/AIDS Research and Interventions
  • HIV Research and Treatment
  • HIV/AIDS drug development and treatment
  • SARS-CoV-2 detection and testing
  • Tuberculosis Research and Epidemiology
  • Biosensors and Analytical Detection
  • Mycobacterium research and diagnosis
  • HIV, Drug Use, Sexual Risk
  • SARS-CoV-2 and COVID-19 Research
  • Adolescent Sexual and Reproductive Health
  • Pneumocystis jirovecii pneumonia detection and treatment
  • Viral gastroenteritis research and epidemiology
  • Global Health and Surgery
  • COVID-19 Clinical Research Studies
  • Biosimilars and Bioanalytical Methods
  • Cancer Genomics and Diagnostics
  • Pneumonia and Respiratory Infections
  • Diagnosis and treatment of tuberculosis
  • Advanced biosensing and bioanalysis techniques
  • COVID-19 and Mental Health
  • HIV-related health complications and treatments
  • Vaccine Coverage and Hesitancy
  • HIV/AIDS Impact and Responses
  • Infectious Diseases and Tuberculosis
  • Focus Groups and Qualitative Methods

University of Washington
2016-2025

National Taiwan University
2024

Program for Appropriate Technology in Health
2024

National Clinical Research
2016-2024

Academia Sinica
2024

University of Alberta
2024

Seattle University
2017-2023

Massachusetts General Hospital
2010-2021

Strategic Analysis (United States)
2020-2021

University of KwaZulu-Natal
2021

The LumiraDx severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen test, which uses a high-sensitivity, microfluidic immunoassay to detect the nucleocapsid protein of SARS-CoV-2, was evaluated for diagnosing disease 2019 (COVID-19) in adults and children across point-of-care settings (NCT04557046). Two paired anterior nasal swabs or two nasopharyngeal were collected from each participant. Swabs tested by SARS-CoV-2 test compared with real-time polymerase chain reaction...

10.1007/s40121-021-00413-x article EN cc-by-nc Infectious Diseases and Therapy 2021-02-24

Current pharmacologic adherence monitoring for antiretrovirals involves expensive, labor-intensive liquid chromatography/tandem mass spectrometry (LC-MS/MS)-based methods. Antibody-based assays can monitor and support in real time. We developed a tenofovir (TFV)-based immunoassay further validated it directly observed therapy (DOT) study.

10.1097/qai.0000000000001971 article EN JAIDS Journal of Acquired Immune Deficiency Syndromes 2019-01-19

The World Health Organization's (WHO) "End TB" strategy calls for development and implementation of novel tuberculosis (TB) diagnostics. Sputum-based diagnostics are challenging to implement often less sensitive in high-priority populations. Nonsputum, biomarker-based tests may facilitate TB testing at lower levels the healthcare system, accelerate treatment initiation, improve outcomes. We provide guidance on design diagnostic accuracy studies evaluating nonsputum, within context WHO's...

10.1093/infdis/jiz356 article EN The Journal of Infectious Diseases 2019-08-02

Since the site of human subjects research has public health, regulatory, ethical, economic, and social implications, we sought to determine global distribution migration clinical using an open-access trial registry.We obtained individual data including location sites, dates operation, funding source (United States government, pharmaceutical industry, or organization), study phase (1, 1/2, 2, 2/3, 3) from ClinicalTrials.gov. We used World Bank's classification each country's economic...

10.1371/journal.pone.0192413 article EN cc-by PLoS ONE 2018-02-28

Testing for mycobacterial lipoarabinomannan (LAM) in urine is a practical but insensitive alternative to sputum testing diagnose tuberculosis (TB) people with HIV (PWH). Here, we evaluated LAM alongside PCR-based tests Mycobacterium (MTB) DNA tongue swabs.

10.1128/jcm.00431-22 article EN Journal of Clinical Microbiology 2022-08-01

Background In sub-Saharan Africa (SSA), adolescent girls and young women (AGYW) ages 15 to 24 years represent <10% of the population yet account for 1 in 5 new HIV infections. Although oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) can be highly effective, low persistence PrEP programs poor adherence have limited its ability reduce incidence among women. Methods findings A total 336 AGYW participating PEPFAR-funded DREAMS program western...

10.1371/journal.pmed.1004097 article EN cc-by PLoS Medicine 2022-09-12

Adolescents and young adults (AYA) living with HIV face several challenges to engaging in care, which can impact adherence antiretroviral therapy (ART). Point-of-care (POC) diagnostics that detect tenofovir urine may be a useful tool support ART adherence, but perspectives from AYA South Africa have not been explored. We conducted in-depth interviews (IDIs) among people (age 18-24) newly diagnosed Cape Town, focus group discussion (FGD) care providers understand their regarding the use of...

10.1371/journal.pone.0318308 article EN public-domain PLoS ONE 2025-01-31

Nucleic acid amplification tests (NAATs) can achieve high accuracy for diagnosing infectious diseases by targeting conserved genetic sequences specific to the target organism. Isothermal NAATs, such as reverse-transcription loop mediated isothermal (RT-LAMP), simplify instrumentation requirements, facilitating point-of-care testing. However, sequence variation due variability cause false negative results. Single-pot multiplex testing improve coverage, but RT-LAMP is complicated requiring...

10.1021/acs.analchem.4c05583 article EN Analytical Chemistry 2025-02-13

Abstract Background Tenofovir diphosphate concentration in red blood cells is an objective measure of long-term oral pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART) adherence. However, current methods for measuring tenofovir are equipment and capital intensive, limiting widespread adoption. Objectives Low cost, rapid diagnostics may drive clinical adoption routine drug level measurement as a tool adherence monitoring disoproxil fumarate-based PrEP ART. We validate simple...

10.1093/jac/dkaf049 article EN Journal of Antimicrobial Chemotherapy 2025-02-25

Real-time, urine tenofovir testing may allow for clinic-based monitoring of adherence to antiretroviral therapy (ART). We aimed assess (1) the acceptability monthly point-of-care over first five months following ART initiation and (2) perspectives on implementation among people living with HIV (PLWH) healthcare providers participating in a randomized controlled trial which used test South Africa. conducted in-depth interviews 20 PLWH six-months post-ART eight providers. assessed (using...

10.1101/2025.03.07.25323040 preprint EN medRxiv (Cold Spring Harbor Laboratory) 2025-03-11

Key stakeholders' involvement is crucial to the sustainability of quality point-of-care (POC) diagnostics services in low-and-middle income countries. The aim this study was explore key stakeholder perceptions on implementation POC rural primary healthcare (PHC) clinics South Africa.We conducted a qualitative encompassing in-depth interviews with multiple stakeholders diagnostic for and resource-limited PHC clinics. Interviews were digitally recorded transcribed verbatim prior thematic...

10.3390/diagnostics7010003 article EN cc-by Diagnostics 2017-01-08

The Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe (DREAMS) Initiative aims to reduce HIV infections among adolescent girls young women (AGYW) in Africa. Oral pre-exposure prophylaxis (PrEP) is offered through DREAMS Kenya eligible AGYW high burden counties including Kisumu Homa Bay. This study examines PrEP persistence community-based delivery settings. We evaluated the program Bay using survival analysis programmatic refill data collected between March December 2017. Among...

10.1080/09540121.2020.1822505 article EN AIDS Care 2020-09-21

BackgroundSince mental health may influence HIV care among people living with (PLHIV), we sought to evaluate the impact of anxiety and depression on ART initiation HIV-related outcomes.MethodsWe conducted a prospective cohort study PLHIV in Umlazi Township KwaZulu-Natal, South Africa. We measured using Patient Health Questionnaire (PHQ-9) Generalized Anxiety Disorder (GAD-7) scale, both which have been validated sub-Saharan Africa, all patients prior receiving positive test. then followed...

10.1016/j.eclinm.2020.100621 article EN cc-by EClinicalMedicine 2021-01-01

The arrival of the next generation advanced diagnostic point-of-care tests was announced on July 28, 2015, when Cepheid and their non-profit partner, FIND, unveiled a new device called GeneXpert Omni.1Cepheid FINDWorld's most portable molecular diagnostics system at AACC.http://ir.cepheid.com/releasedetail.cfm?releaseid=924108Date: 2015Google Scholar Although this might seem to be yet another rapid nucleic acid amplification test, it is small (23 cm tall), lightweight (1 kg), easy use,...

10.1016/s2214-109x(15)00186-2 article EN cc-by The Lancet Global Health 2015-10-19

Introduction Several supply chain components are important to sustain point-of-care (POC) testing services in rural settings. To evaluate the availability of POC diagnostic tests Ghana's primary healthcare (PHC) clinics, we conducted an audit management for Upper East Region's (UER) PHC Ghana determine reasons/causes deficiencies. Material and methods We a review accessible diagnostics 100 clinics UER, from February March 2018. used monitoring tool adopted World Health Organization...

10.1371/journal.pone.0211498 article EN cc-by PLoS ONE 2019-02-27

Introduction Providing antiretroviral therapy (ART) for millions of people living with HIV requires efficient, client-centred models differentiated ART delivery. In South Africa, the Centralised Chronic Medication Dispensing and Distribution (CCMDD) programme allows over 1 million to collect chronic medication, including ART, from community pick-up points. We aimed explore how CCMDD influences engagement in care. Methods performed in-depth interviews focus group discussions clients receiving...

10.1136/bmjopen-2019-035412 article EN cc-by BMJ Open 2020-05-01
Coming Soon ...